BioMarin Reports Mixed Q4 Results with Earnings Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy BMRN?
Source: Benzinga
- Earnings Report: BioMarin's Q4 earnings came in at $0.46 per share, missing the analyst consensus of $0.63, indicating potential concerns about profitability that may affect investor confidence.
- Sales Performance: The company reported quarterly sales of $875 million, surpassing the analyst estimate of $827.969 million, suggesting strong market demand that could lay the groundwork for future growth.
- Future Outlook: BioMarin projects FY2026 sales between $3.325 billion and $3.425 billion, falling short of market expectations of $3.507 billion, reflecting a cautious stance on future growth.
- Acquisition Plans: The announcement of the acquisition of Amicus, expected to close in Q2, is viewed as a strategic opportunity to expand patient reach and enhance revenue growth over the next decade.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMRN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMRN
Wall Street analysts forecast BMRN stock price to rise
19 Analyst Rating
14 Buy
5 Hold
0 Sell
Moderate Buy
Current: 61.110
Low
60.00
Averages
87.35
High
120.00
Current: 61.110
Low
60.00
Averages
87.35
High
120.00
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioMarin Receives FDA Approval for PALYNZIQ in Pediatric Patients
- FDA Approval: BioMarin Pharmaceutical Inc. announced that its PALYNZIQ (pegvaliase-pqpz) has received approval from the U.S. FDA for use in pediatric patients aged 12 and older with phenylketonuria, marking a significant advancement in treatment options.
- Unique Therapy: PALYNZIQ is the only approved enzyme substitution therapy that effectively reduces blood phenylalanine (Phe) concentrations, helping patients with phenylketonuria improve their health outcomes and overall quality of life.
- European Market Expansion: BioMarin is also seeking approval from the European Medicines Agency to expand PALYNZIQ's indication to adolescents aged 12 and older in the European Union, further broadening its market reach.
- Market Reaction: Although BioMarin's stock rose by 1.01% to $61.73 during regular trading on Friday, it fell by 3.92% to $59.31 in after-hours trading, indicating mixed market reactions to the new approval.
See More
FDA Approves PALYNZIQ for Adolescent PKU Treatment
- FDA Approval: BioMarin announced that the FDA has approved PALYNZIQ for adolescents aged 12 and older with PKU, marking an expansion of the drug's application in the adolescent population and is expected to improve their daily management.
- Clinical Trial Results: In the PEGASUS study, the PALYNZIQ group showed an average reduction of 473 μmol/L in blood phenylalanine (Phe) levels at Week 72, compared to a mere -19 μmol/L in the diet-only group, indicating a significant efficacy difference that could transform treatment for adolescent PKU patients.
- Increased Dietary Freedom: As the only enzyme substitution therapy, PALYNZIQ allows patients to manage Phe levels without dietary restrictions, helping adolescents alleviate the burdens of dietary limitations while facing academic and independence challenges.
- Safety and Side Effects: While PALYNZIQ's side effects include injection site reactions and hypersensitivity, most adverse reactions occurred during the induction phase in clinical trials, with a significant decrease in frequency during maintenance, indicating a favorable long-term safety profile.
See More
FDA Approves PALYNZIQ for Pediatric PKU Treatment in Adolescents
- FDA Approval for New Indication: BioMarin announced that PALYNZIQ has received FDA approval for use in adolescents aged 12 and older with PKU, marking an expansion of the drug's application in the adolescent population and is expected to improve their daily management.
- Significant Clinical Study Results: In the PEGASUS study, the PALYNZIQ group showed an average reduction of 473 μmol/L in blood phenylalanine (Phe) levels at Week 72, compared to only 19 μmol/L in the control group, demonstrating PALYNZIQ's significant advantage in controlling Phe levels.
- Benefits for Adolescent Patients: The study revealed that 44.4% of participants reached Phe levels below guideline recommendations after treatment, with 75% of patients achieving levels below 120 μmol/L and an average Phe reduction of 828 μmol/L, indicating PALYNZIQ's potential benefits for adolescents.
- Safety and Tolerability: While common side effects in adolescents included injection site reactions and headaches, PALYNZIQ's safety profile was well managed in clinical trials, particularly during the maintenance phase, where the incidence of adverse reactions significantly decreased.
See More
BioMarin Reports Mixed Q4 Results with Earnings Miss
- Earnings Report: BioMarin's Q4 earnings came in at $0.46 per share, missing the analyst consensus of $0.63, indicating potential concerns about profitability that may affect investor confidence.
- Sales Performance: The company reported quarterly sales of $875 million, surpassing the analyst estimate of $827.969 million, suggesting strong market demand that could lay the groundwork for future growth.
- Future Outlook: BioMarin projects FY2026 sales between $3.325 billion and $3.425 billion, falling short of market expectations of $3.507 billion, reflecting a cautious stance on future growth.
- Acquisition Plans: The announcement of the acquisition of Amicus, expected to close in Q2, is viewed as a strategic opportunity to expand patient reach and enhance revenue growth over the next decade.
See More
BioMarin Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: BioMarin's total revenue for 2025 reached $3.22 billion, reflecting a 13% year-over-year increase, with enzyme therapies growing by 9% and Voxzogo revenues soaring by 26%, indicating strong performance and heightened market demand in the biopharmaceutical sector.
- Strategic Acquisition Progress: The company completed its acquisition of Inozyme and expects to finalize the acquisition of Amicus next quarter, which will enhance its enzyme therapy portfolio and further solidify BioMarin's leadership position in the rare disease treatment market.
- Optimistic Future Outlook: The CFO projected total revenues for 2026 to be between $3.325 billion and $3.425 billion, with enzyme therapies and Voxzogo revenues expected to be between $2.225 billion to $2.275 billion and $975 million to $1.025 billion respectively, demonstrating the company's confidence in future growth.
- Robust Cash Flow: BioMarin reported a non-GAAP diluted EPS of $3.15 for 2025, with operating cash flow reaching $828 million, a 45% increase year-over-year, providing strong financial support for future investments and acquisitions.
See More
BioMarin Pharmaceutical Q4 Earnings Beat Expectations Despite EPS Miss
- Earnings Highlights: BioMarin Pharmaceutical reported a Q4 non-GAAP EPS of $0.46, missing expectations by $0.10, yet achieved revenues of $875 million, a 17.1% year-over-year increase, surpassing market expectations by $39.97 million, indicating strong market performance.
- 2026 Guidance: The company projects total revenues for 2026 to be between $3.325 billion and $3.425 billion, although this is below the consensus estimate of $3.38 billion, the expected growth in enzyme therapies and VOXZOGO revenue suggests potential for continued expansion, with forecasts of $2.225 billion to $2.275 billion and $975 million to $1.025 billion, respectively.
- EPS Forecast: BioMarin anticipates a non-GAAP diluted EPS of between $4.95 and $5.15 for 2026, which, while below the consensus of $5.33, still reflects confidence in the company's future profitability.
- Financing Activities: Recently, BioMarin completed an $850 million senior notes issuance and a $2 billion term loan syndication, providing ample funding for operations and R&D, thereby further solidifying its market position.
See More
BioMarin Receives FDA Approval for PALYNZIQ in Pediatric Patients
- FDA Approval: BioMarin Pharmaceutical Inc. announced that its PALYNZIQ (pegvaliase-pqpz) has received approval from the U.S. FDA for use in pediatric patients aged 12 and older with phenylketonuria, marking a significant advancement in treatment options.
- Unique Therapy: PALYNZIQ is the only approved enzyme substitution therapy that effectively reduces blood phenylalanine (Phe) concentrations, helping patients with phenylketonuria improve their health outcomes and overall quality of life.
- European Market Expansion: BioMarin is also seeking approval from the European Medicines Agency to expand PALYNZIQ's indication to adolescents aged 12 and older in the European Union, further broadening its market reach.
- Market Reaction: Although BioMarin's stock rose by 1.01% to $61.73 during regular trading on Friday, it fell by 3.92% to $59.31 in after-hours trading, indicating mixed market reactions to the new approval.
See More
FDA Approves PALYNZIQ for Adolescent PKU Treatment
- FDA Approval: BioMarin announced that the FDA has approved PALYNZIQ for adolescents aged 12 and older with PKU, marking an expansion of the drug's application in the adolescent population and is expected to improve their daily management.
- Clinical Trial Results: In the PEGASUS study, the PALYNZIQ group showed an average reduction of 473 μmol/L in blood phenylalanine (Phe) levels at Week 72, compared to a mere -19 μmol/L in the diet-only group, indicating a significant efficacy difference that could transform treatment for adolescent PKU patients.
- Increased Dietary Freedom: As the only enzyme substitution therapy, PALYNZIQ allows patients to manage Phe levels without dietary restrictions, helping adolescents alleviate the burdens of dietary limitations while facing academic and independence challenges.
- Safety and Side Effects: While PALYNZIQ's side effects include injection site reactions and hypersensitivity, most adverse reactions occurred during the induction phase in clinical trials, with a significant decrease in frequency during maintenance, indicating a favorable long-term safety profile.
See More
FDA Approves PALYNZIQ for Pediatric PKU Treatment in Adolescents
- FDA Approval for New Indication: BioMarin announced that PALYNZIQ has received FDA approval for use in adolescents aged 12 and older with PKU, marking an expansion of the drug's application in the adolescent population and is expected to improve their daily management.
- Significant Clinical Study Results: In the PEGASUS study, the PALYNZIQ group showed an average reduction of 473 μmol/L in blood phenylalanine (Phe) levels at Week 72, compared to only 19 μmol/L in the control group, demonstrating PALYNZIQ's significant advantage in controlling Phe levels.
- Benefits for Adolescent Patients: The study revealed that 44.4% of participants reached Phe levels below guideline recommendations after treatment, with 75% of patients achieving levels below 120 μmol/L and an average Phe reduction of 828 μmol/L, indicating PALYNZIQ's potential benefits for adolescents.
- Safety and Tolerability: While common side effects in adolescents included injection site reactions and headaches, PALYNZIQ's safety profile was well managed in clinical trials, particularly during the maintenance phase, where the incidence of adverse reactions significantly decreased.
See More
BioMarin Reports Mixed Q4 Results with Earnings Miss
- Earnings Report: BioMarin's Q4 earnings came in at $0.46 per share, missing the analyst consensus of $0.63, indicating potential concerns about profitability that may affect investor confidence.
- Sales Performance: The company reported quarterly sales of $875 million, surpassing the analyst estimate of $827.969 million, suggesting strong market demand that could lay the groundwork for future growth.
- Future Outlook: BioMarin projects FY2026 sales between $3.325 billion and $3.425 billion, falling short of market expectations of $3.507 billion, reflecting a cautious stance on future growth.
- Acquisition Plans: The announcement of the acquisition of Amicus, expected to close in Q2, is viewed as a strategic opportunity to expand patient reach and enhance revenue growth over the next decade.
See More
BioMarin Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: BioMarin's total revenue for 2025 reached $3.22 billion, reflecting a 13% year-over-year increase, with enzyme therapies growing by 9% and Voxzogo revenues soaring by 26%, indicating strong performance and heightened market demand in the biopharmaceutical sector.
- Strategic Acquisition Progress: The company completed its acquisition of Inozyme and expects to finalize the acquisition of Amicus next quarter, which will enhance its enzyme therapy portfolio and further solidify BioMarin's leadership position in the rare disease treatment market.
- Optimistic Future Outlook: The CFO projected total revenues for 2026 to be between $3.325 billion and $3.425 billion, with enzyme therapies and Voxzogo revenues expected to be between $2.225 billion to $2.275 billion and $975 million to $1.025 billion respectively, demonstrating the company's confidence in future growth.
- Robust Cash Flow: BioMarin reported a non-GAAP diluted EPS of $3.15 for 2025, with operating cash flow reaching $828 million, a 45% increase year-over-year, providing strong financial support for future investments and acquisitions.
See More
BioMarin Pharmaceutical Q4 Earnings Beat Expectations Despite EPS Miss
- Earnings Highlights: BioMarin Pharmaceutical reported a Q4 non-GAAP EPS of $0.46, missing expectations by $0.10, yet achieved revenues of $875 million, a 17.1% year-over-year increase, surpassing market expectations by $39.97 million, indicating strong market performance.
- 2026 Guidance: The company projects total revenues for 2026 to be between $3.325 billion and $3.425 billion, although this is below the consensus estimate of $3.38 billion, the expected growth in enzyme therapies and VOXZOGO revenue suggests potential for continued expansion, with forecasts of $2.225 billion to $2.275 billion and $975 million to $1.025 billion, respectively.
- EPS Forecast: BioMarin anticipates a non-GAAP diluted EPS of between $4.95 and $5.15 for 2026, which, while below the consensus of $5.33, still reflects confidence in the company's future profitability.
- Financing Activities: Recently, BioMarin completed an $850 million senior notes issuance and a $2 billion term loan syndication, providing ample funding for operations and R&D, thereby further solidifying its market position.
See More
